Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP788611.RATZxU_ejhnBVncmdEYqI2chIpIgq5jmAV-zASXK9Brjo130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP788611.RATZxU_ejhnBVncmdEYqI2chIpIgq5jmAV-zASXK9Brjo130_assertion type Assertion NP788611.RATZxU_ejhnBVncmdEYqI2chIpIgq5jmAV-zASXK9Brjo130_head.
- NP788611.RATZxU_ejhnBVncmdEYqI2chIpIgq5jmAV-zASXK9Brjo130_assertion description "[Sunitinib is currently being evaluated in advanced human thyroid carcinomas, based on the rationale that the vascular endothelial growth factor and platelet-derived growth factor receptors and the RET/PTC rearrangement are valuable targets for the treatment of this malignancy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP788611.RATZxU_ejhnBVncmdEYqI2chIpIgq5jmAV-zASXK9Brjo130_provenance.
- NP788611.RATZxU_ejhnBVncmdEYqI2chIpIgq5jmAV-zASXK9Brjo130_assertion evidence source_evidence_literature NP788611.RATZxU_ejhnBVncmdEYqI2chIpIgq5jmAV-zASXK9Brjo130_provenance.
- NP788611.RATZxU_ejhnBVncmdEYqI2chIpIgq5jmAV-zASXK9Brjo130_assertion SIO_000772 22442268 NP788611.RATZxU_ejhnBVncmdEYqI2chIpIgq5jmAV-zASXK9Brjo130_provenance.
- NP788611.RATZxU_ejhnBVncmdEYqI2chIpIgq5jmAV-zASXK9Brjo130_assertion wasDerivedFrom befree-20150227 NP788611.RATZxU_ejhnBVncmdEYqI2chIpIgq5jmAV-zASXK9Brjo130_provenance.
- NP788611.RATZxU_ejhnBVncmdEYqI2chIpIgq5jmAV-zASXK9Brjo130_assertion wasGeneratedBy ECO_0000203 NP788611.RATZxU_ejhnBVncmdEYqI2chIpIgq5jmAV-zASXK9Brjo130_provenance.